Replimune Group Inc (REPL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $13.07 (+1.55%), Market cap $0.43B, 52-week low–high $1.70 ~ $12.63.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group
Financial statements, price targets, institutional (13F) holdings and related news for Replimune Group Inc are updated in real time on BlackAll Trade.
Replimune Group Inc trades at $13.07 (+1.55%). Real-time quotes and charts are available on BlackAll Trade.
Replimune Group Inc has a market cap of about $0.43B.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immuno